B19; Erythrovirus B19; Fifth Disease; Human Parvovirus; Slapped Cheek disease
Test ID
PARVS
General Information
Useful for:
Serologic detection of recent or past parvovirus B19 infection
This assay may be used to determine the serostatus of patients at risk for infection with parvovirus B19
This test is intended for patients with at least 7 days of symptoms or asymptomatic individuals with recent exposure to parvovirus B19
For patients with acute, symptomatic presentation, order either PARVP (Parvovirus B19, Molecular Detection, PCR, Plasma) or PARVO (Parvovirus B19, Molecular Detection, PCR, Varies)
Specimen Type
Serum
Specimen Requirements
Preferred: Seurm Gel (SST)
Acceptable: Red Top
Minimum Sample Volume
0.5 mL
Stability
Refrigerated (preferred): 14 days
Frozen: 14 days
Unacceptable Specimen Conditions
Gross hemolysis
Gross lipemia
Gross icterus
Heat-inactivated specimen
Limitations
Specimens collected prior to seroconversion may yield negative IgM or IgG antibody results, while specimens collected after IgM antibody levels have begun to decline may yield negative IgM antibody results. Follow-up testing of convalescent samples may be beneficial to establish infection status
The continued presence or absence of antibodies cannot be used to determine the success or failure of therapy
Test results of specimens from immunocompromised patients may be difficult to interpret
Testing should not be performed as a screening procedure for the general population. Testing should only be done when clinical evidence suggests the diagnosis of parvovirus B19-associated disease
The performance of this test has not been established on neonates and immunocompromised patients
Specimens containing antinuclear antibodies may produce equivocal or positive test results in the IgM assay
Epstein-Barr virus-positive specimens may produce positive or equivocal test results in the IgM assay
Assay performance characteristics have not been established for matrices other than serum
